Clinical trials: Plasma Concentration
- Condition Plasma Concentration
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Asthma
Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)
To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.
- Trial name
- NCT00751413
- Testing
- Comparator: MK0633
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)
To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.
- Trial name
- NCT00646789
- Testing
- Comparator: MK0633
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bronchiolitis
PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)
The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.
- Trial name
- NCT00394069
- Testing
- MK-0476, montelukast sodium
- Volunteers
- 14 people
- Sponsor
- Organon and Co
Acute Cannabis-induced CNS Depression
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to…
- Trial name
- NCT06017622
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Anebulo Pharmaceuticals
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Magnetic Resonance Imaging
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
This is an open-label, multi-center study involving babies 0-2 months of age who have liver problems (pathology) and need to have their liver and possibly, the bile ducts imaged using magnetic resonance imaging and injection of a…
- Trial name
- NCT02084628
- Testing
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Attention Deficit Hyperactivity Disorder
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
- Trial name
- NCT00485407
- Testing
- Atomoxetine Hydrochloride
- Where
- 2 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
HIV Infections
A Study of L-735,524 in HIV-Positive Children and Adolescents
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate ( MK-639; Crixivan ) in HIV-seropositive older children and adolescents.
- Trial name
- NCT00002351
- Testing
- Indinavir sulfate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Acne
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
The primary objective of this study is to evaluate the skin and plasma concentrations of minocycline in subjects undergoing treatment of acne vulgaris with oral extended release minocycline.
- Trial name
- NCT02695446
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BioPharmX, Inc.
Bronchiolitis
Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)
The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 1 to < 3 months of age with bronchiolitis.
- Trial name
- NCT00394160
- Testing
- MK0476, Montelukast Sodium /Duration of Treatment : 14 Days
- Volunteers
- 12 people
- Sponsor
- Organon and Co
Infantile Spasms
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
The primary objective of the study is to evaluate vigabatrin pharmacokinetics (PK) in neonates receiving vigabatrin for infantile spasms (IS); and to determine the safety of vigabatrin.
- Trial name
- NCT01413711
- Testing
- Vigabatrin
- Sponsor
- Lundbeck LLC
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA